Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
Latest Information Update: 02 Nov 2023
At a glance
- Drugs Insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms ONSET 2
- Sponsors Novo Nordisk; Novo Nordisk Pharma
- 06 Oct 2023 Results (n=786) assessing develop a machine learning model to predict the effect of a change in basal insulin dose on FBG in people with T2D presented at the 59th Annual Meeting of the European Association for the Study of Diabetes
- 22 Nov 2018 Results of post hoc analysis exploring whether mealtime fast-acting insulin aspart treatment provided an advantage in postprandial plasma glucose (PPG) control vs. insulin aspart in people with Type 2 diabetes receiving high doses of bolus insulin published in the Diabetic Medicine
- 08 Dec 2017 Results of a post-hoc analysis from Onset-2 and Onset-3 studies, presented at the 2017 Congress of the International Diabetes Federation